Back to top

Analyst Blog

We recently reiterated a Neutral recommendation on United Therapeutics (UTHR - Analyst Report).

While the company reported strong third-quarter results, United Therapeutics suffered a major blow in October with the US Food and Drug Administration (FDA) issuing a complete response letter (CRL) for its new drug application for oral Remodulin (treprostinil). The company was looking to get oral Remodulin approved for the treatment of pulmonary arterial hypertension (PAH).

Although United Therapeutics said that it intends to gain approval for the candidate within four years, we have low visibility on the company’s development plans for the candidate.

The company's lead product is Remodulin, an injectable formulation of treprostinil, indicated for the treatment of PAH in patients with New York Heart Association (NYHA) Class II-IV symptoms. Remodulin is approved for both subcutaneous (SC) and intravenous (IV) use. The other two PAH products in the company’s portfolio are Adcirca (tadalafil) and Tyvaso.

United Therapeutics holds a strong position in the PAH market with three approved products targeting this indication. Lead product Remodulin continues to look very strong in both the IV and SC forms. EU approval for the IV formulation, received in late December 2011, should drive sales further. The company is looking to launch Remodulin in new territories including Japan and China. The Japanese market could bring in incremental sales of about $100 million.

Although we believe United Therapeutics' existing PAH product portfolio will drive strong top-and bottom-line growth, we remain concerned about the company’s dependence on Remodulin for revenues.

Remodulin, which accounted for 57.9% of total sales in 2011, is currently facing a generic challenge from Sandoz, Novartis’ (NVS - Analyst Report) generic division. The company needs to develop products that could help make up for the loss of revenues in the event of genericization of Remodulin.

United Therapeutics currently holds a Zacks #2 Rank (Buy). Stocks that currently carry a Zacks #1 Rank (Strong Buy) include Valeant Pharma (VRX - Analyst Report) and Astellas Pharma (ALPMY).

Please login to or register to post a comment.

New to Zacks?

Start Here

Zacks Investment Research


Are you a new Zacks Member or a visitor to

Top Zacks Features

My Portfolio Tracker

Is it Time to Sell?

One of the most important steps you can take today is to set up your portfolio tracker on Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts.

More Zacks Resources

Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.

Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.

Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.

My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.

Zacks #1 Rank Top Movers for Zacks #1 Rank Top Movers

Company Symbol Price %Chg
CENTURY ALU… CENX 22.53 +4.50%
ERBA DIAGNO… ERB 2.91 +4.30%
PLANAR SYST… PLNR 4.31 +3.86%
MALLINCKROD… MNK 72.17 +3.83%
GTT COMMUNI… GTT 12.06 +3.52%